Potassium citrate effects on kidney handling of oxalate and citrate in adults
Official title: Oxalate and Citrate in Humans - Response to Citrate
Run by University of Chicago · NCT06944223 · Data updated 2026-11-12
This project will test whether a single oral dose of potassium citrate changes how the kidneys handle oxalate and citrate in adults with and without calcium oxalate kidney stones.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | June 1, 2027 |
| Registry record updated | December 16, 2025 |
| Trial ID | NCT06944223 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–70 who either have at least one calcium-based kidney stone or have no stone history with normal 24‑hour urine oxalate, can stop diuretics/alkali for the study, and have preserved kidney function are ideal candidates.
✕Probably not a fit
People with primarily uric acid, cystine, or struvite stones, significant CKD (eGFR <75 mL/min/1.73 m²), extreme urine citrate levels, or who cannot stop diuretics/alkali are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
At the University of Chicago Clinical Research Center, investigators will enroll two groups of 12 adults each: people with a history of calcium oxalate kidney stones and people without stones and with normal 24‑hour urine oxalate. Participants will receive a single oral dose of potassium citrate and have blood and urine collected over six hours to measure fractional excretion of oxalate and citrate. Changes from baseline will be compared and oxalate fractional excretion will be adjusted for changes in citrate to test a possible transporter-mediated link between the two ions. Key exclusions include non–calcium stone types, significant chronic kidney disease (eGFR <75 mL/min/1.73 m²), extreme urine citrate values, and inability to stop diuretics or alkali supplements.
Why it matters
Potential benefit: If successful, the results could clarify a transporter link between citrate and oxalate and guide better prevention strategies for calcium oxalate kidney stones.
How similar studies have gone: Prior research shows citrate changes urinary chemistry and can reduce stone risk, but the specific transporter-mediated coupling between oxalate and citrate in humans remains largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Stone formers (SF): * Age 18-70 * History of at least one calcium-based kidney stone Non-stone formers (NSF): * Age 18-70 * No history of kidney stone * 24-hour urine oxalate within laboratory normal range (\<50 mg/day) Exclusion Criteria: History of primarily uric acid, cysteine, or struvite stones History of severe acid-base abnormality, very low (less than 100 mg/day) or very high (greater than 1500 mg/day) urine citrate Any controls or stone former (SF) participants who cannot stop diuretic medication or alkali supplementation for the course of the study period Chronic kidney disease (glomerular filtration rate \<75 milliliters per minute per 1.73 square meters \[mL/min/1.73 m²\]) Non-stone formers (NSF) and stone formers (SF) with extreme levels of urine citrate will be excluded from this small initial study to reduce heterogeneity and remove focus from the extremes of citrate levels.
Where it's running
-
University of Chicago Medical Center
Chicago, Illinois, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emergency urinary drainage followed by PCNL in obstructive urosepsis
Doctors test whether the method of emergency drainage (retrograde ureteral stent or percutaneous nephrostomy) affects how well patients do after undergoing definitive PCNL.
-
Observation vs Upfront Surgery for Asymptomatic Kidney Stones in Children and Adults
This trial tests whether watching asymptomatic kidney stones or performing upfront surgery is better for reducing life disruption in patients aged 6 and older.
-
Two-Tier Virtual Reality Education to Reduce Anxiety Before Kidney Stone Surgery
This study tests whether a two-tier VR preoperative education approach can lower anxiety and improve knowledge and self-care in adults undergoing urolithiasis surgery.
-
Tamsulosin 0.4 mg with Tadalafil 5 mg versus 2.5 mg to reduce symptoms from ureteral stents
This will test whether adding Tadalafil at 5 mg or 2.5 mg to Tamsulosin 0.4 mg better reduces stent-related symptoms for adults with a double-J ureteral stent after stone removal.
-
Ureteral access sheath: omitting versus placing a stent after ureteroscopy
We will test if leaving out a ureteral stent after ureteroscopy with an access sheath works as well as placing a stent for pre-stented adults with kidney or ureteral stones.
-
Using a flexible suction sheath with flexible ureteroscopy for lower-pole kidney stones
This trial will test whether adding a flexible, navigable suction sheath to flexible ureteroscopy helps adults with lower-pole kidney stones become stone-free more often and avoid repeat procedures.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.